VRC-EBOADC069-00-vp

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), University of Maryland, Baltimore

Conditions

Ebola Virus DiseaseHealthy Adult Immune Responses to VaccineHemorrhagic Fever

Phase 1

Safety, Tolerability, and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO), VRC-EBOADC069-00-VP, in Healthy Adults

CompletedNCT02231866

National Institute of Allergy and Infectious Diseases (NIAID)Healthy Adult Immune Responses to Vaccine

Start: 2014-08-27End: 2017-04-05Updated: 2018-07-05

Ebola CVD-Mali #2000 (Bivalent) VRC-EBOAdc069-00-vp (cAd3-EBO)

CompletedNCT02368119

University of Maryland, BaltimoreEbola Virus Disease, Hemorrhagic Fever

Start: 2015-03-31End: 2016-09-27Updated: 2019-09-26

Related Papers

Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials.

2024-03-2910 citations

Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial.

2015-11-04162 citations

Chimpanzee Adenovirus Vector Ebola Vaccine

New England Journal of Medicine2014-11-26281 citations